Advertisement

Search Results

Advertisement



Your search for Seema A. Khan, MD matches 21 pages

Showing 1 - 21


breast cancer

Seema Khan, MD, on Ductal Carcinoma in Situ: Central MRI and a 12-Gene Expression Assay to Optimize Local Therapy

Seema Khan, MD, of Northwestern University and the Robert H. Lurie Comprehensive Cancer Center, discusses the 5-year clinical outcomes of ECOG-ACRIN 4112, a prospective trial that supports the omission of radiotherapy after surgery in patients with ductal carcinoma in situ who have a low DCIS score ...

breast cancer

Skipping Adjuvant Radiotherapy May Not Impact Risk of Recurrence or Progression in Patients With Low-Risk DCIS

Patients with low-risk ductal carcinoma in situ (DCIS) who skipped adjuvant radiotherapy after breast-conserving surgery had comparable 5-year outcomes to those with high-risk DCIS who received adjuvant radiotherapy, according to results from the E4112 clinical trial presented at the 2023 San...

From a Sleepy Town in Pakistan, Seema A. Khan, MD, MPH, Emerges as a Leader in Surgical Oncology

In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Seema A. Khan, MD, MPH, Professor of Breast Cancer Surgery at Northwestern Medicine, Feinberg School of Medicine. Along with her surgical and academic pursuits, Dr. Khan is an active...

breast cancer

Risk-Reducing Bilateral Mastectomy May Help Women With High-Penetrance Genetic Mutations to Avoid Cancer

“Risk-reducing bilateral mastectomy allows a woman with a high-penetrance breast cancer-causing mutation to avoid an encounter with the experience of breast cancer diagnosis and treatment,” Seema A. Khan, MD, MPH, stated at the 2022 Lynn Sage Breast Cancer Symposium.1 For these women, by avoiding...

breast cancer

Does Early Locoregional Therapy for the Primary Site Improve Survival in Newly Diagnosed Metastatic Breast Cancer?

In the phase III ECOG-ACRIN E2108 trial reported in the Journal of Clinical Oncology, Seema A. Khan, MD, MPH, and colleagues found no difference in overall survival with early locoregional therapy vs continued systemic therapy among women with newly diagnosed stage IV breast cancer and an intact...

breast cancer

Fear of Side Effects and Lack of Awareness: Barriers to Greater Use of Risk-Reducing Medications for Breast Cancer

A “big problem, maybe the major one,” with risk-reducing medications for breast cancer is low uptake among women at high risk of breast cancer,” Seema A. Khan, MD, told participants at the 2021 Annual Lynn Sage Breast Cancer Symposium.1 Dr. Khan is Professor of Surgery and the Bluhm Family...

breast cancer

Risk-Reducing Medications for Breast Cancer Are Becoming Safer and More Tolerable

Risk-reducing medications for breast cancer may be effective for many women, and recently reported and ongoing trials have led to improvements in their tolerability and safety, Seema A. Khan, MD, reported at the 2021 Annual Lynn Sage Breast Cancer Symposium (virtual).1 Dr. Khan is Professor of...

breast cancer

No Survival Benefit from Local Therapy in de Novo Metastatic Breast Cancer Study

Results of the phase III E2108 study indicate that surgery and radiotherapy given after systemic treatment afforded no additional survival benefit among women with newly diagnosed metastatic breast cancer. The practice may, however, reduce locoregional progression of disease, according to a report...

breast cancer

Study Finds No Survival Benefit From Local Therapy for de Novo Metastatic Breast Cancer

Women presenting with newly diagnosed de novo metastatic breast cancer derived no additional survival benefit from surgery and radiotherapy given after systemic treatment, although the practice may reduce locoregional progression of disease, according to the results of the phase III E2108 study...

breast cancer

Seema A. Khan, MD, MPH, on Metastatic Breast Cancer: Systemic vs Locoregional Therapies

Seema A. Khan, MD, MPH, of the Lynn Sage Comprehensive Breast Center, discusses phase III trial results showing that in newly diagnosed metastatic stage IV breast cancer, locoregional treatment of the primary tumor did not offer a greater survival benefit than systemic therapy (Abstract LBA2).

breast cancer

Early Local Therapy Did Not Extend Survival in Patients With Newly Diagnosed Metastatic Breast Cancer

Women who present at diagnosis with advanced breast cancer have faced an unanswered question: will local therapy, consisting of surgery and radiation to the tumor in the breast, prolong survival compared to the traditional treatment of systemic treatment alone? Now, data from the randomized phase...

breast cancer

When to Consider Local Therapy for Stage IV Breast Cancer

Local therapy for stage IV breast cancer has not been proven to increase overall survival, yet there are some cases where local therapy could be considered outside a clinical trial. For patients with intact asymptomatic primary tumors, local therapy could be offered if distant disease is well...

breast cancer

For Postmenopausal Women With Ductal Carcinoma in Situ: NSABP B-35 and IBIS-II DCIS Trials Offer a Choice of Endocrine Therapy

The past year has produced an embarrassment of riches regarding the value of aromatase inhibitors for women with ductal carcinoma in situ of the breast. The long-awaited NSABP B-35 study matured and was reported by Margolese and colleagues at the 2015 ASCO Annual Meeting this past summer, followed...

solid tumors

Resection of Metastatic Lesions Extends Survival in Multiple Tumor Types

Surgical oncologists urged other cancer providers to appreciate the potentially curative role that surgery can play in the management of many stage IV solid tumors, in a session during the American College of Surgeons 97th Annual Clinical Congress in San Francisco. Pulmonary Metastases Stephen G....

breast cancer

Ablation of Small Primary Breast Tumors: The Next Step in Local Therapy?

Local treatment of breast cancer is trending toward less invasive procedures that achieve comparable outcomes to standard interventions. What will the next step along this continuum be? According to Michael S. Sabel, MD, a surgical oncologist at the University of Michigan Comprehensive Cancer...

Expert Point of View: Seema A. Khan, MD

Responding to the results of the ACOSOG Z1071 study, Seema A. Khan, MD, Professor of Surgery at Northwestern University Feinberg School of Medicine, Chicago, urged caution in adopting the practice of sentinel lymph node surgery after chemotherapy for some patients with breast cancer at this time....

breast cancer
colorectal cancer
lung cancer
prostate cancer

Ongoing NCI-Funded Clinical Trials Actively Recruiting Patients With Advanced Cancer

This issue of The ASCO Post launches a Clinical Trials Resource Guide to increase awareness of NCI-funded phase I, II, and III clinical studies for your patients with advanced cancer. All of the studies are listed on the National Institutes of Health website at ClinicalTrials.gov. The clinical...

David Gius, MD, PhD, Named Co-leader of Northwestern’s Women’s Cancer Research Program

David Gius, MD, PhD, has been named Co-leader of the Women’s Cancer Research Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, a position he has served in interim since February 2014. Dr. Gius, a nationally recognized radiation oncologist and researcher, is a...

breast cancer

Andrew Seidman, MD, and Seema Khan, MD, MPH on Controversies in the Management of DCIS

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Seema A. Khan, MD, MPH, of the Lynn Sage Comprehensive Breast Center, discuss the session moderated by Dr. Khan on this important topic (Session ES8).

breast cancer

Study Compares Tamoxifen Gel Applied to the Breast With Oral Tamoxifen in Women With DCIS

A randomized, double-blind, placebo-controlled phase II trial comparing the antiproliferative effect of transdermal 4-hydroxytamoxifen gel (4-OHT), a potent antiestrogenic metabolite of tamoxifen, applied to the breast and oral tamoxifen in women with ductal carcinoma in situ (DCIS), has found the...

breast cancer

Gene Profile May Help Identify Risk for Hormone-sensitive, Hormone-insensitive Breast Cancer

The overexpression or underexpression of a newly identified set of genes related to lipid metabolism may help physicians identify whether or not a woman is at risk for hormone receptor–positive or hormone receptor–negative breast cancer and to subsequently tailor prevention strategies...

Advertisement

Advertisement




Advertisement